[市場調查報告書] 癌症治療市場

Abstract

Cancer is the second leading cause of death by disease in the United States, exceeded only by heart disease. Traditionally cancer has been treated with surgery, chemotherapy, hormones and radiation therapy, alone or in combination. Emerging technologies include photodynamic therapy, gene therapy, biological therapy (immunotherapy) and angiogenesis inhibitors. Pharmaceutical and biotechnology companies are investing billions of dollars to search out and develop weapons for the arsenal in the war against cancer.

This TriMark Publications report provides an overview of the global market for cancer therapeutics. The examination focuses on the efforts of biotechnology companies and pharmaceutical firms to incorporate new technologies for developing anti-cancer drugs into their corporate strategies. This study examines cancer therapeutic products now on the market, as well as those currently under development that might be commercialized in the near future. Additionally, the report profiles a number of firms that are actively involved in marketing and developing of products to be used in the treatment of cancer-both large multinational corporations. The analysis also provides an overview of the disease and data on cancers by site or type. It provides incidence and mortality data for different types of the disease. In addition, the report provides a summary of each of the therapies that are being used to treat cancer.

1. Overview

1.1 Introduction
1.2 Goals and Objectives
1.3 Study, Scope and Format
1.4 Methodology
1.5 Summary of Major Findings

2. Introduction to the Cancer Therapeutic Market

3. Cancer Therapeutics Market Overview

3.1 Cancer Therapeutics in the Pharmaceutical and Biotech Industry
3.2 Business Analysis of the Cancer Market
- 3.2.1 Growth Potential
- 3.2.2 Demographics of Cancer
- 3.2.3 The Global Market for Cancer Therapies
  - 3.2.3.1 European Cancer Market
  - 3.2.3.2 The Environment in the U.K. for Clinical Research into New Anti-Cancer Therapies
  - 3.2.3.3 The Suitability of Current U.K. and E.U. Regulatory Regimes
  - 3.2.3.4 Comments on the Current E.U. Regulatory Environment
3.3 The Pharmaceutical Industry
3.4 Cancer Therapies
- 3.4.1 Market Size
3.5 New Product Trends
- 3.5.1 Chemotherapy
- 3.5.2 Hormone Therapy
- 3.5.3 Photodynamic Therapy and Photosensitizers
- 3.5.4 Gene Therapy
  - 3.5.4.1 Tumor-Suppressor Gene Therapy
  - 3.5.4.2 Immunomodulatory Gene Therapy
  - 3.5.4.3 Suicide Gene Therapy
- 3.5.5 Radiation Therapy
- 3.5.6 Farnesyl Transferase Inhibitors (FTIs)
- 3.5.7 Genetic Screening
- 3.5.8 Biological Therapies
- 3.5.9 Interferons
- 3.5.10 Interleukins
- 3.5.11 Tumor Necrosis Factor (TNF)
- 3.5.12 Colony-Stimulating Factors (CSFs)
- 3.5.13 Monoclonal Antibodies (MAbs)
- 3.5.14 Cancer Vaccines
- 3.5.15 Anti-Sense Therapy
- 3.5.16 Adjuvants
- 3.5.17 Angiogenesis Inhibitors
- 3.5.18 Hyperthermia
- 3.5.19 Transplants
  - 3.5.19.1 Bone Marrow Transplants
  - 3.5.19.2 Stem Cell Transplants

4. The Disease of Cancer

4.1 Incidence of Cancer
- 4.1.1 U.S. Statistics
- 4.1.2 Global Statistics
4.2 Causes of Cancer
4.3 Risk Factors
- 4.3.1 Smoking
- 4.3.2 Diet
- 4.3.3 Radiation
- 4.3.4 Occupational Risks
- 4.3.5 Medicine and Infection
- 4.3.6 Environmental Pollution
- 4.3.7 Reproductive Factors
- 4.3.8 Socio-Economic Factors
4.4 Cancer Costs

5. Specific Cancers

5.1 Bladder Cancer
- 5.1.1 Overview of the Disease
- 5.1.2 Diagnosis and Staging
- 5.1.3 Therapy
- 5.1.4 Test for Bladder Cancer Analyzes DNA in Urine
- 5.1.5 Drugs in Development
5.2 Brain Cancer
- 5.2.1 Overview of the Disease
- 5.2.2 Treatment Options
5.3 Breast Cancer
- 5.3.1 Overview of the Disease
- 5.3.2 Therapeutic Drugs
- 5.3.3 Market Overview for Breast Cancer Therapeutics
5.4 Cervical Cancer
- 5.4.1 Overview of the Disease
- 5.4.2 Treatment Options
5.5 Colon Cancer
- 5.5.1 Overview of the Disease
- 5.5.2 Treatment Options
- 5.5.3 Market Overview for Colon Cancer Therapeutics
5.6 Leukemia
- 5.6.1 Overview of the Disease
- 5.6.2 Treatment Options
5.7 Lymphoma
- 5.7.1 Overview of the Disease
- 5.7.2 Treatment Options
5.8 Lung Cancer
- 5.8.1 Overview of the Disease
- 5.8.2 Treatment Options
- 5.8.3 Breakthrough Treatments for Lung Cancer
- 5.8.4 Market Overview for Lung Cancer Therapeutics
5.9 Ovarian Cancer
- 5.9.1 Overview of the Disease
- 5.9.2 Treatment Options
5.10 Prostate Cancer
- 5.10.1 Overview of the Disease
- 5.10.2 Treatment Options

6. Corporate Profiles

6.1 AstraZeneca Plc
6.2 Biogen Idec, Inc.
6.3 Bristol-Myers Squibb
6.4 Genentech, Inc.
6.5 Genta, Inc.
6.6 Genzyme Oncology
6.7 GlaxoSmithKline Plc
6.8 ImClone Systems, Inc.
6.9 Medarex
6.10 Millennium Pharmaceuticals, Inc.
6.11 Novartis AG
6.12 Onyx Pharmaceuticals, Inc.
6.13 OSI Pharmaceuticals, Inc.
6.14 Pfizer
6.15 Regeneron Pharmaceuticals, Inc.
6.16 Roche
6.17 Sanofi-Aventis

7. References

7.1 Online References for Cancer
7.2 Print Sources
7.3 Product Approvals for Cancer Indications

INDEX OF TABLES

Table 2.1: The 646 Medicines in Development for Cancer, 2006
Table 2.2: Drug Approvals for Cancer Indications, 1996-2007
Table 3.1: Opportunities for Molecular-Targeting Therapeutics for Cancer
Table 3.2: Top U.S. Biotechnology Companies by Market Capitalization
Table 3.3: Top Pharmaceutical Companies by Market Capitalization
Table 3.4: Clinical Development for some of Hoffman-La Roche Products
Table 3.5: Global Pharmaceutical Industry R&D Spending, 1995-2006
Table 3.6: U.S. Government NIH Research Budget, 1995-2007
Table 3.7: Health Spending as Percentage of GDP by Country
Table 3.8: Spending on Health by Country
Table 3.9: Annual Spending on Cancer Drugs Per Person
Table 3.10: Patients Per Cancer Specialist
Table 3.11: World Healthcare Cancer Therapeutics Markets by Region
Table 3.12: The Projected Growth in the U.S. Market for Cancer Therapeutics, 1998-2006
Table 3.13: The Projected Growth in the European Market for Cancer Therapeutics, 1998-2006
Table 3.14: The Projected Growth in the Japanese Market for Cancer Therapeutics, 1998-2006
Table 3.15: Cancer Vaccines Approved or in Phase III Clinical Trials
Table 3.16: Anti-Angiogenic Drugs in Clinical Trial for Cancer
Table 4.1: Estimates of New Cancer Cases and Deaths in the U.S. by Sex for all Cancer Sites, 2007
Table 4.2: Estimated New Cancer Cases and Deaths for Ten Leading Cancer Sites in the U.S., by Sex, 2007
Table 4.3: Estimated Worldwide Number of New Cancer Cases and Deaths by Leading Cancer Sites and by Level of Economic Development, 2007
Table 4.4: Estimated Number of New Cancer Cases and Deaths by World Area, 2007
Table 4.5: Cancer Death Rates per 100,000 Population (and Rank) for all Cancer Sites by Country, 2006
Table 4.6: Genes and Cancer Risk
Table 4.7: Carcinogens in the Workplace
Table 5.1: Drugs Used in Bladder Cancer Therapy
Table 5.2: Drugs in Development for Bladder Cancer
Table 5.3: Medicines in Development for Brain Cancer
Table 5.4: Classes of Chemotherapy Drugs Used to Treat Breast Cancer
Table 5.5: U.S. Sales of Doxorubicin, 2001-2009
Table 5.6: New Therapeutics for Breast Cancer
Table 5.7: Other Classes of Drugs Used to Treat Breast Cancer
Table 5.8: Worldwide AstraZeneca' s Nolvadex Sales, 2000-2005
Table 5.9: Aromatase Inhibitors
Table 5.10: Worldwide Sales Estimates for Arimidex, 2000-2008
Table 5.11: Worldwide Herceptin Sales, 1999-2005
Table 5.12: Innovative Drug Therapies applied to the Breast Cancer Market Sector
Table 5.13: Treatment Regimens for Advanced Breast Cancer
Table 5.14: Medicines in Development for Cervical Cancer
Table 5.15: New Therapies for Colon Cancer
Table 5.16: Worldwide Sales for Xeloda, 2001-2005
Table 5.17: Worldwide Sales of Tomudex, 1998-2005
Table 5.18: Medicines in Development for Leukemia
Table 5.19: Pricing of Novartis' Gleevec in Various Strengths in the U.S.
Table 5.20: Medicines in Development for Lymphoma
Table 5.21: U.S. Sales of Rituxan, 1999-2005
Table 5.22: Cytotoxics for Lung Cancer Therapy
Table 5.23: Anti-Angiogenics for Lung Cancer
Table 5.24: Drugs in Development for Lung Cancer
Table 5.25: Current Therapies for Ovarian Cancer
Table 5.26: Emerging Therapies for Ovarian Cancer
Table 5.27: New Development Therapies for Ovarian Cancer
Table 5.28: New Drug Types for Ovarian Cancer
Table 5.29: Medicines in Development for Prostate Cancer
Table 6.1: Potential Therapeutic Indications and Development Stages
Table 6.2: Products in Clinical Development in Phase II and III (Including Additional Indications)
Table 7.1: Drugs Currently Approved for the Treatment of Cancer